Bristol-Myers 4Q net rises 9 pct on cost cuts NewsOK.com Rheumatoid arthritis drug Orencia's sales rose 26 percent to $325 million and sales jumped 47 percent to $211 million for breakthrough melanoma drug Yervoy. However, transplant rejection drug Nulojix, approved in June 2011, generated just $4 million in ... |
